The global veterinary auto-immune therapeutics market is projected to be appraised at USD 71,720.6 million by 2033, up from USD 42,815.7 million in 2023, advancing at a CAGR of 5.3% from 2023 to 2033.
The adoption of veterinary auto-immune therapeutics is on the surge as several new ways of treating autoimmune diseases in animals using various drugs and other therapies like surgeries and stem cell therapies are evolving worldwide.
The demand for these drugs also rises as used to reduce the symptoms associated with the specific autoimmune disease. Furthermore, auto-immune disease treatment is gaining more attention owing to an increased threat of zoonotic disease transfer among humans, in turn, positively impacting the veterinary auto-immune therapeutics market outlook.
Hence, the growing incidence of zoonotic disease transfer is changing business operations of the animal healthcare industry as emergency care.
| Attributes | Details |
|---|---|
| Veterinary Auto-immune Therapeutics Market Share (2022) | USD 41,087.7 million |
| Veterinary Auto-immune Therapeutics Market Share (2023) | USD 42,815.7 million |
| Veterinary Auto-immune Therapeutics Market Share (2033) | USD 71,720.6 million |
| Veterinary Auto-immune Therapeutics Market Share (2023 to 2033) | 5.3% |
The veterinary auto-immune therapeutics market growth is fuelled by veterinary hospitals as they are offering a wide range of therapeutic services for companion animals. An increase in the prevalence of autoimmune illness and a rise in Research and Development efforts to provide the best possible treatments in tandem with a surge in the use of therapeutics for the condition are also anticipated to contribute to the market growth in coming years.
Moreover, the market is expanded by the rise in autoimmune disease incidence and early illness detection, and the recent introduction of cutting-edge therapies during the forecast period. A significant number of late-stage pipeline medications are also present, including tocilizumab, certolizumab, baricitinib, etanercept, secukinumab, elotuzumab, abatacept, PF-06438179, apremilast, golimumab, certolizumab, ustekinumab, tofacitinib, and others.
The increasing transfer of zoonotic diseases among immunosuppressed patients is a prime factor responsible for the rising awareness of the auto-immune disease among companion animals.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The high threat of HIV transfer from the animal source to a person with suppressed immunity, and the transfer of allergic components from companion animals to family members are also spiking the demand for veterinary auto-immune therapeutics.
The growing incidence of autoimmune diseases in livestock animals has decreased the quality of meat consumed especially in pharmaceutical manufacturing. Moreover, the focus on livestock health among African countries which are the main exporters of livestock is further surging the demand for autoimmune disease therapy.
However, limited therapy options for animals in developing countries and a lack of awareness are hindering the growth of the veterinary auto-immune therapeutics market.
Due to numerous government-sponsored programs that promote these diagnostic tests, North America held the largest market share in the world for the diagnosis of animal auto-immune diseases accounting for 37.2% in 2022. The increased demand for all healthcare improvements for animal welfare is a result of the region's increased meat consumption.
There is a huge knowledge of the effects and impacts of auto-immune disorders thanks to their prevalence, in turn expanding the veterinary auto-immune therapeutics market size.
Principal Consultant
Europe held 26.5% of the veterinary auto-immune therapeutics market share in 2022. The main factor driving rising utilization rates is the increased awareness of animal autoimmune diseases brought on by programs in research, support, advocacy, and education.
The European Commission is pursuing a number of initiatives to raise public knowledge of the factors that may contribute to the onset of animal auto-immune diseases, thereby spurring the adoption of such therapeutics.
A Med City biotech company received more than USD 330,000 in federal money to explore gene therapy for dogs and possibly people in the future. The National Institutes of Health has given a USD 337,443 Phase I Small Business Innovation Research grant to Life Engine Animal Health, or LEAH Labs, led by CEO and co-founder Dr. Wes Wierson.
With assistance from the Mayo Clinic, Wierson developed gene editing methods that are used by LEAH Labs. The Mayo Clinic granted a license to LEAH Labs for the study. Downtown Rochester is where LEAH Labs is headquartered.
In the second quarter of 2022, pilot tests for the start-up's first product, a CAR-T cell therapy for cancerous dogs, are anticipated to begin. The objective is to develop a treatment for canine B cell lymphoma malignancy. An estimated 300,000 canines every year succumb to that form of cancer, which is analogous to Non-lymphoma Hodgkin's in people.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Market players are employing various organic and inorganic strategies including mergers & acquisitions, partnerships, collaborations, etc. in order to consolidate their position in the veterinary auto-immune therapeutics market.
A few of the recent developments in the veterinary auto-immune therapeutics market are:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | United States, Canada, Germany, United Kingdom, Nordic, Russia, BENELUX, Poland, France, Spain, Italy, Czech Republic, Hungary, Rest of EMEAI, Brazil, Peru, Argentina, Mexico, South Africa, Northern Africa, GCC Countries, China, Japan, South Korea, India, ASEAN, Thailand, Malaysia, Indonesia, Australia, New Zealand, Others |
| Key Segments Covered | Therapy Type, Disease Indication, Animal Type, Distribution Channel, Region |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, Trend Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
The market is estimated to secure a valuation of USD 42,815.7 million in 2023.
The market is estimated to expand at a CAGR of 5.3% between 2023 and 2033.
The top 3 market players are Aratana Therapeutics Inc., Pfizer Inc., and Vet-Stem Inc.
North America generated 37.2% revenue in 2022.
The market is likely to be valued at USD 71,720.6 million in 2033.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy Type 5.1. Corticosteroids, Azathioprine 5.2. Cyclosporine 5.3. Mycophenolate 5.4. Leflunomide 5.5. Cyclophosphamide 5.6. Levothyroxine 5.7. Folic Acid 5.8. Hydroxychloroquine 5.9. Chloroquine 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Indication 6.1. Hypothyroidism 6.2. Pemphigus Disease 6.3. Canine Lupus 6.4. Auto-Immune Hemolytic Anemia 6.5. Bullous Pemphigoid 6.6. Discoid Lupus Erythematosus (DLE) 6.7. Immune-related arthritis 6.8. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Animal Type 7.1. Companion Animal 7.2. Dogs 7.3. Cats 7.4. Horse 7.5. Live Stock Animal 7.6. Cattle 7.7. Swine 7.8. Poultry 7.9. Fish 7.10. Sheep 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 8.1. Veterinary Hospitals 8.2. Veterinary Clinics 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. South Asia and Pacific 9.6. East Asia 9.7. Middle East and Africa 10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Key Countries Market Analysis 18. Market Structure Analysis 19. Competition Analysis 19.1. Aratana Therapeutics Inc. 19.2. Pfizer Inc. 19.3. Vet-Stem, Inc. 19.4. Ambrx Inc. 19.5. Taconic Biosciences, Inc. 19.6. JBS Value (US$ Million) 19.7. Virbac 19.8. Eli Lilly and Company 19.9. Jaguar Animal Health Inc. 19.10. Novartis AG 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Veterinary Auto-Immune Therapeutics Market
